. 2019 Jun 7;28(2):925–932. doi: 10.1007/s00520-019-04875-1

Table 3.

CSF and antibiotic use

Characteristic, n (%)	Patients with NSCLCN = 3866
CSF use
Primary prophylaxis^a	709 (18.3)
Secondary prophylaxis^b	242 (6.3)
Treatment^c	636 (16.5)
Prophylactic oral antibiotics	1200 (31.0)

CSF colony-stimulating factor, NSCLC non-small-cell lung cancer

^aFirst receipt of CSF within first 5 days of first cycle of the index course

^bFirst receipt of CSF within first 5 days of subsequent cycles of the index course

^cFirst receipt of CSF in any given cycle after cycle day 5